(Total Views: 643)
Posted On: 05/28/2023 5:34:46 PM
Post# of 154119
Quote:
And if TAK is looking for an oncology and/or liver drug with the potential to generate tens of billions of revenue that it could buy relatively cheaply -- voila!
So, if TAK is to collaborate with CytoDyn in NASH, they would do it with their drug TAK-647 aka Ontamalimab which is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission in patients with ulcerative colitis (UC).
TAK/Shire terminated their clinical trials of Ontamalimab for Chrons Disease and Ulcerative Colitis as seen here: https://adisinsight.springer.com/drugs/800025580
LL is a G7 CCR5 blockade, so the two monoclonal antibodies could work together as they attach to two different G proteins in the cell membrane.
Apparently, TAKeda must have data that patients who were taking Ontamalimab, had improvement in NASH, be it steatosis or fibrosis or both. So they are actively recruiting for Phase 1 for NASH right now.
I see a very real possibility that they choose to combine with LL and become the collaborating CRO with CytoDyn for a Phase 2b NASH trial since they've already done Phase 3 trials for UC and CD but were terminated.
(10)
(0)
